At daily intake levels of 25–40 grams, EPG is associated with dose-dependent gastrointestinal symptoms, including gas with discharge, diarrhea, oily spotting, oily evacuation, and soft or liquid stools. These symptoms correlate directly with EPG concentration in the diet, but they are significantly reduced at lower doses of around 10 grams/day, which is generally well tolerated. This tolerance profile distinguishes EPG from earlier fat substitutes like olestra, which caused more severe digestive issues. EPG acts as a "lipid sink" during digestion, partially inhibiting the absorption of fat-soluble nutrients. Studies report reduced levels of beta-carotene (a Vitamin A precursor) and Vitamin K in human serum, alongside less consistent declines in liver stores of Vitamins A, D, and E in animal models. Despite these reductions, no clinical deficiencies or adverse health outcomes were observed in trials, even at high doses. The mechanism is attributed to EPG binding fat-soluble compounds, limiting their bioavailability without causing deficiency symptoms. Comprehensive studies show no evidence of acute, subchronic, or chronic toxicity, genotoxicity, or carcinogenicity in animal models at tested doses. Clinical trials confirm no significant adverse effects on organ systems or overall health at typical consumption levels. Extremely high doses (60–150 grams/day) in human studies caused minor, transient changes in liver enzymes and cholesterol, but these resolved post-trial and were deemed clinically insignificant. EPG has been granted GRAS (Generally Recognized as Safe) status by the FDA.